leadf
logo-loader
viewImmuPharma PLC

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3 lupus clinical trial

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion Pharmaceuticals, ImmuPharma’s licensing partner for Lupuzor™.

Dr Franklin says at the meeting, Avion together with the FDA will discuss key points and following the meeting the FDA will respond giving their guidance.

He says a conditional approval would allow the marketing of Lupuzor™ prior to the completion of the new Phase 3, based on the clinically significant data previously generated in the completed Phase 2 and 3 clinical trials to date.

Quick facts: ImmuPharma PLC

Price: 8.92 GBX

AIM:IMM
Market: AIM
Market Cap: £22.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Immupharma: The Life Sciences Division's Dr Malik says shares are 'oversold'...

The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on ImmuPharma PLC (LON:IMM). Malik examines the company's flagship drug Lupuzor - a treatment for the autoimmune disease Lupus. ImmuPharma recently updated the market on progress within its lupus drug, Lupuzor,...

1 week, 3 days ago

2 min read